#fda #clinicaltrials #clinicalresearch #sma #spinalmuscularatrophy #rarediseaseresearch | Rare...
On May 30, 2022, it was announced that the FDA has approved EvrysdiĀ® (risdiplam) for use in babies under two months of age with Spinal Muscular Atrophy (SMA). This is exciting news for not only the...
linkedin.com